Characteristics | Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|
HR | 95% CI | P value | HR | 95% CI | P value | |
Model 1 (n = 200) | ||||||
 Age (years) | 1.063 | 1.014–1.115 | 0.011 |  |  | 0.20 |
 Gender |  |  | 0.48 |  |  | 0.42 |
 TA-eGFR (mL/min/1.73 m2) | 0.978 | 0.957–1.000 | 0.048 | 0.971 | 0.945–0.998 | 0.03 |
 TA-ALB (g/L) | 0.778 | 0.663–0.913 | 0.002 | 0.772 | 0.636–0.937 | 0.008 |
 UPE at month 3 (g/day) | 1.000 | 1.000–1.001 | 0.016 |  |  | 0.40 |
Model 2 (n = 200) | ||||||
 Age (years) | 1.063 | 1.014–1.115 | 0.011 |  |  | 0.25 |
 Gender |  |  | 0.48 |  |  | 0.32 |
 Non-remission (vs remission) | 5.877 | 2.031–17.006 | 0.001 | 4.995 | 1.436–17.365 | 0.011 |
 TA-eGFR (mL/min/1.73 m2) | 0.978 | 0.957–1.000 | 0.048 | 0.962 | 0.933–0.992 | 0.013 |
 TA-ALB (g/L) | 0.778 | 0.663–0.913 | 0.002 | 0.806 | 0.673–0.966 | 0.019 |
 UPE at month 3 (g/day) | 1.000 | 1.000–1.001 | 0.016 |  |  | 0.99 |
Model 3 (n = 160) | ||||||
 Age (years) | 1.063 | 1.014–1.115 | 0.011 |  |  | 0.52 |
 Gender |  |  | 0.48 |  |  | 0.13 |
 Relapse (vs non-relapse) | 12.602 | 1.443–110.058 | 0.022 | 12.629 | 1.446–110.32 | 0.021 |
 TA-eGFR (mL/min/1.73 m2) | 0.978 | 0.957–1.000 | 0.048 |  |  | 0.06 |
 TA-ALB (g/L) | 0.778 | 0.663–0.913 | 0.002 |  |  | 0. 12 |
 UPE at month 3 (g/day) | 1.000 | 1.000–1.001 | 0.016 |  |  | 0.28 |